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Brief Methodological Report 
 
TITLE: Validity and Reliability of the Decision Regret Scale in Cancer Patients 
Receiving Adjuvant Chemotherapy 
 
Abstract 
Objetctives Decisional regret is an indicator of satisfaction with the treatment decision 
and can help to identify those patients who need more support and evaluate the efficacy 
of decision support interventions. The objetives of this study are, 1) to evaluate the 
psychometric properties of the Decision Regret Scale and 2) to analyze the moderating 
effect of psychological distress on functional status and regret in patients with cancer 
following adjuvancy.  
Methods A prospective, multicenter cohort of 403 patients who completed the Decision 
Regret Scale (DRS), Health-related Quality of Life (EORTC QLQ-C30), and Brief 
Symptom Inventory (BSI). The evaluation was conducted six months after receiving 
adjuvant treatment in patients with resected cancer. 
Results After treatment, most participants (51.9%) experienced no decision regret; 
33.7% felt mild regret, and 14.4% exhibited high levels of regret. The Spanish version 
of the DRS demonstrated satisfactory properties: it had a strong, clear unidimensional 
factorial structure with substantial loadings. Decisional regret was related with lower 
scores on functional, symptom, and quality of life scales, and higher levels of 
psychological distress (all p=0.001). Psychological distress was found to have a 
moderating effect on the relationship between functio al state and decision regret.  
Conclusions The Spanish version of the DRS is a reliable, valid tool to evaluate regret 
and post-decisional quality in clinical practice and further highlights the potential 
clinical implications of psychological distress for the relation between physical status 
and regret. 
 


















Decision-making as to the advisability of receiving or rejecting adjuvant-
chemotherapy that seeks to lessen the risk of recurr nce after tumor resection is 
complex for cancer patients1. Medical oncologists provide their patients with 
information about the risks and benefits of chemotherapy to facilitate an informed 
decision2.  
Regret is a negative emotional reaction resulting from the untoward effects of a 
given choice. Evaluating regret in medical decision-making is uncommon, given the 
lack of reliable, valid measures. Although a systematic review of regret measures 
yielded ten instruments3, only three were applicable to decision-making in the context 
of medical care: Regret Scale4 that appraises regret in men with prostate cancer; 
Anticipatory Regret Questionnaire5 that captures a sense of regret in the future about 
donating blood, and Decision Regret Scale (DRS)6 that gauges regret in patients who 
have already made a medical decision6.  
Regret has been correlated with low degrees of satisfac on with preoperative 
information, depression, anxiety, and stress7; with negative body image and 
psychological distress8 in patients with breast cancer, and with impaired quality of life 
(QoL) in patients with prostate cancer9. The psychological factors involved in regret 
include perception of health and psychological distress, both of which are common in 
individuals with cancer beginning adjuvant treatment10. With this background, this 
study seeks to analyze the psychometric p operties of DRS in patients with resected 
cancer treated with adjuvant chemotherapy and to examine the moderating effect of 
psychological distress between functional status and regret.  
Methods 
Research Design and Study Population 
A multi-institutional, prospective, observational research design was used to examine 
the incidence of decision regret with respect to adjuvant therapy and evaluate the 
psychometrics of DRS. Within this design, DRS data were collected at a single time 
point (see below); consequently, all analyses performed in this study are cross-sectional. 
The study pooled consecutive patients recruited at 14 teaching hospitals in Spain from 
June 2015 to December 2017 and was approved by the Ethics Review Board at each 
institution and by the Spanish Agency of Medicines and Medical Devices (AEMPS). 















Inclusion criteria were: aged >18 years, have a histologically confirmed, non-advanced, 
resected solid tumor, be eligible for adjuvant treatment.  
Sample characteristics 
A total of 403 cancer patients (55.3% women and 44.7% men) completed the 
assessment 6 months after receiving adjuvant-chemotherapy. Mean age was 58.4 years 
(range 25-84); most were married or partnered (79.4%), unemployed (58.8%), and had 
attained a primary level of education (61%). The most common tumor sites were colon 
(43.9%) and breast (31%), stages I-II (53.6%). All received chemotherapy and 30.8% 
received associated radiotherapy.  
DRS adaptation. The DRS was first developed in English6. It was adapted to Spanish 
by forward-backward translation12 of the English version by two independent bilingual 
translators; both of whom are native Spanish speakers and fluent in English. The two 
Spanish versions were translated back into English by a professional translator with 
experience in medical translation and by two medical doctors who had not been 
involved in the forward translation. Another two bilingual translators blind to the 
original English version back-translated the revised Spanish version; finally, the study 
directors compared and synthesized the back-translation with the original questionnaire, 
culminating in a final Spanish version of the DRS.  
Data collection  
Data collection was similar for all hospitals. Following a full explanation of study 
objectives and procedures, candidates were invited to participate and complete the 
questionnaire at home. Study participation was voluntary and anonymous. Participants 
completed the questionnaires individually, with no time limit. This visit was structured 
according to standard practice at each center, although it was agreed that as a minimum, 
risk of relapse, options for adjuvant treatment, risk of adverse effects, and possible 
treatment efficacy should be discussed with the patients. Participant’s flow chart is 
given in Fig.1.  
Insert Figure 1 here 
Decision Regret Scale. The DRS is a five-item, self-report scale to evaluate 
decisional regret. Items are scored on five-point Likert scales, ranging from 1 to 5. 
Scores were reversed for items 2 and 4; mean scores were obtained and then converted 















indicating greater regret. Internal consistency reliability estimates (α=0.81-0.92) for 
oncology patients6.  
Health-related Quality of Life. The EORTC QLQ-C30 (V.3.0) is a cancer-specific 
measure of HRQoL13. It consists of 30 items that assess quality of life (QoL) as regards 
functional scales, and a global QoL scale14. All scale scores are linearly transformed to 
a 0–100 scale. Higher scores represent a higher levl of functioning or QoL, and more 
symptom burden. Cronbach’s alpha estimates range from 0.74 to 0.8813.  
Brief Symptom Inventory-18. The BSI-1815 is a self-report inventory designed to 
evaluate psychological distress, using a 5-point scale from 0-4. Raw scores are 
converted to T-scores based on gender-specific normative data. Higher scores indicate 
greater psychological distress15. Cronbach’s alpha estimates range from 0.72 to 0.8416.  
Data analysis 
The internal psychometric properties of the DRS scale were examined using a three-
stage series of analyses. First, basic item descriptive statistics were explored. Second, a 
confirmatory factor analysis (CFA) was performed to study the scale’s expected 
unidimensionality, as well as the pattern of item-trait relations. Third, provided that the 
DRS behaved as essentially unidimensional, the reliability of its scores was scrutinized. 
The unidimensional CFA solution in step 2 above wasfitted using robust weighted least 
squares estimation with mean and variance corrected fit statistics as implemented in the 
Mplus program17. Model fit and appropriateness were assessed with three groups of 
measures. First, model residuals and relative fit were evaluated with SRMS 
(Standardized Root Mean Square Residual) and Root Mean Squared Error of 
Approximation (RMSEA) statistics. Second, relative comparative fit was examined with 
the comparative fit index (CFI) (as a relative measure of fit with respect to the null 
independence model). Finally, additional indices of appropriateness were also obtained 
to verify the strength and replicability of the solution (h index), as well as closeness to 
unidimensionality (Explained Common Variance ECV index)18 with the FACTOR 
software program19.  As for reference values, CFI values ≥0.95 are indicative of good 
model fit20, whereas SRMR values ≤0.08 and RMSEA values ≤0.06 are considered 
satisfactory fitting models21,22. Finally, once the proposed structure had been fitted and 
found suitable, DRS score reliability was assessed using the omega coefficient23. 
Validity analysis proceeded in two stages. First, the product-moment correlations 















Second, multiple linear regression was used to examine the potential moderating effects 
between QoL and psychological distress on decision regret. Validity analyses were 
conducted using IBM-SPSS 23.0 statistical software package (SPSS, INC., Chicago, 
III) for Windows. 
Results 
Descriptive analyses 
The mean DRS score was 10.6 (SD=15.4). Most participants 51.9% (n=209) 
experienced no decision regret. Degrees of decisional regret were not significantly 
influenced by gender (F(1,401)=0.503, p=0.478), age (≤60 years vs >60 years; 
F(1,401)=1.310, p=0.253), or education (primary level vs ≥high school; F(1,401)=0.133, 
p=0.716). Likewise, decisional regret was not significantly affected by treatment 
(chemotherapy vs chemo- and radiotherapy) (F(1,401)=1.203, p=0.273). 
DRS item score distributions were unimodal and asymmetrical (positively skewed). 
Item-total correlations were all >0.40. Provided that the scale behaves 
unidimensionally, this result indicates that the itms have adequate discriminating 
power and are strongly related to the construct they m asure (see table 1).  
Insert Table 1 here 
CFA analysis 
Given (a) the ordered-categorical nature of the respon e variables, (b) the skewed 
item distributions, and (c) the relatively high item discriminating power, we opted to use 
the underlying-variables approach and fit the FA model to the inter-item polychoric 
correlation matrix24. The initial fit of the unidimensional model was unacceptable by all 
standards. Inspection of the results, however, clearly revealed that the sole source of 
misfit was the correlated residual between items 2 and 4. This result, confirmed by 
cross-validation, is to be expected since (a) these are the two reverse-keyed items (i.e., a 
method effect) and (b) they share specific content. After freeing the residual covariance, 
an almost perfect fit was obtained: SRMS=0.01; RMSEA=0.0; CFI=1. The remaining 
indices of appropriateness were also relatively acceptable. The ECV value was 0.81, 
indicating that the solution could indeed be considere  essentially unidimensional, 
whereas the h index was 0.91, suggesting that the solution was both robust and 
replicable26. Note that all loadings are well above their corresponding standard error, 
and those of items 1, 3, and 5 are particularly high. This result is consistent with the 















strongly related to the construct they measure. The om ga reliability estimate for the 
raw scores was 0.87, which is remarkably high, given th  limited number of items.  
Validity analyses 
After treatment, higher levels of decisional regret correlated significantly with lower 
scores on the functional (r= -0.316, p=0.001) and global QoL (r=  -0.257, p=0.001) 
subscales. Higher levels of decisional regret, however, correlated significantly with 
higher symptom (r= 0.278, p=0.001) and psychological distress (r= 0.297, p=0.001) 
scores. Of the four interactions tested, one was significant — the moderational effect of 
psychological distress on the relationship between functional status and regret (B= -
.015, 95% CI [0.02, 0.05], β= -.96, t=2.87, p=0.004). The analysis indicated that 12.2% 
of the variation in regret was explained by functional status and the interaction effects 
between functional status and psychological distres (F(3,397)=19.51, p<0.001) (see table 
2 and Figure 2) Thus, when functional status is high, there are minimal differences in 
regret experienced by both patients suffering from high and those with low levels of 
psychological distress.  
Insert Table 2 and Figure 2 here 
Given the positively skewed distribution (i.e., floor effects) of DRS scores, as well as 
measurement error in the reported measures, the validity results discussed thus far are 
likely to be somewhat attenuated. Therefore, these r ults can be better considered as 
lower limits, and the latent relations between the constructs of interest (decisional 
regret, psychological distress…) are likely to be stronger than the product-moment 
correlations and proportions of shared variance based on what the ‘proxy’ measures 
suggest.  
Discussion 
This study presents important findings. First, few patients with cancer (14.4%) regret 
having undergone adjuvant treatment after surgery for a non-metastatic tumor, despite 
its side effects. Our results are consistent with previous studies that have evaluated 
decision regret in oncological patients and suggest that most patients are satisfied with 
their treatment and present low levels of decisional regret8,9,25. Studies using the DRS to 
assess decision regret found that 19.5% of women with breast cancer regretted 
reconstruction following mastectomy8 and only 4% of men with prostate cancer 















As for internal psychometrics, the Spanish version of the DRS displayed good 
properties. It had a clear, strong unidimensional factorial structure with substantial 
loadings and the scores derived from it demonstrated cceptable reliability even for 
individual assessment. These results are remarkable, t king into account that they were 
obtained with only 5 items. Despite these good prope ties, however, there is still room 
for further improvement. The two negatively keyed items had weaker discriminating 
power than the remaining ones and shared residual vari nce that had to be accounted for 
in the model to achieve an acceptable level of fit. One hypothesis is that participants 
(Spanish patients) confuse the wording of these items and follow the pattern of response 
for positively worded statements26. Other researchers have suggested that the inclusion 
of the reverse worded items increases the risk of inattention and confusion27,28. 
Replacing negatively worded items with alternative items to measure decision regret 
would help eliminate error and improve the scale’s variance.  
As regards external validity, convergent validity was acceptable and a pattern of 
significant correlations with health outcomes was ob erved in the expected direction. 
This is particularly relevant, since adjuvant chemotherapy is the treatment of choice 
after surgery for certain locally advanced cancers, such as breast and colon ca cer, and 
treatment tends to have immediate, negative repercussions for patients’ physical status, 
symptomatology, and global QoL29, although their adverse effects are usually 
temporary29. Our results indicate that the patients most likely to regret treatment are 
those with worse QoL, including physical status, presence of symptoms, and greater 
psychological distress. Other authors found that regret was greater in patients with heart 
disease with worse perceived physical health30, and regret was associated with 
depression, anxiety, and stress in women with breast c ncer31. We did not find 
differences in regret by gender, age, educational level, or type of treatment. It must be 
remembered that in medical contexts, patients tend to provide socially acceptable 
responses on questionnaires that rate their attitude oward the quality of care and 
treatment received7. We have attempted to avoid this problem by guaranteei g 
participants’ anonymity.  
The moderating role of psychological distress provides a more complete view of the 
relation between physical status and regret. Thus, when physical status is adequate, no 
significant differences are seen among cancer patients with respect to regret, whatever 
their level of psychological distress. In contrast, when health is perceived as poor, those 















decisional regret. These findings correlate in partwith the Monitoring Process Model32, 
according to which a person’s perception of their own health impacts how they confront 
and respond to it. To the best of our knowledge, thre are no other studies that analyze 
the moderating role of psychological distress betwen physical status and decision 
regret in oncology patients. In future studies, it would be interesting to ascertain if this 
regret is reversible; i.e., whether decision regret d creases if/when patients’ physical 
and/or psychological status improve(s).  
This study has a series of limitations. First, the sample o is heterogenous, to enable 
subgroup analyses to be performed based on tumor site. Second, because the study was 
designed to include a single evaluation of regret, information about causality cannot be 
examined, nor can we offer a possible explanation as to how regret evolves over time. 
Third, it may be that the results of our study cannot be extrapolated to patients with 
advanced tumors, whose clinical situation and prognosis differ markedly. Finally, we 
must be cautious when interpreting these results, bearing in mind that all the patients 
eligible to participate did so voluntarily, which may have introduced a self-selection 
bias. Likewise, a limitation of clinical significance is the absece of appropiately 
matched comparison samples of patients to assess regret garding their decision not to 
proceed with chemotherapy. Future research is requiered to explore the contribuiton of 
other psychological factors that may influence decision regret, e.g., outcome 
expectations and fear of recurrence.   
Conclusions 
The results of this study indicate that the Spanish version of the DRS exhibits 
satisfactory psychometric properties, with a clear and strong unidimensional factorial 
structure, and acceptable reliability and validity. The moderating effect of psychological 
distress in the relation between physical status and regret tells us that the effect of 
physical status on regret is more accentuated if pat ents display greater psychological 
distress. This result points to the need to perform individualized interventions that 
promote improvement of physical status following chemotherapy. In general, after 
completing adjuvant treatment, there are fewer visits to the oncologist. However, some 
individuals, due to their deteriorated physical and psychological condition as a result of 
residual toxicity of chemotherapy, will require more frequent visits to help them 















rejection. Maintaining a certain level of psychological wellbeing will likely benefit 
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Table 1. Item Descriptive Statistics of the Spanish DRS (n=403) 
Questions Mean SD Skews R item-total 
It was the right decision 1.22 0.57 2.7 (.1) 0.62 
I regret the choice 1.65 1.33 1.8 (.1) 0.59 
I would make the same choice if I had to do it over again 1.28 0.76 3.4 (.1) 0.61 
The choice did me a lot of harm 1.73 1.23 1.6 (.1) 0.60 
The decision was a wise one 1.26 0.55 2.8 (.1) 0.62 
Note. SD: standard deviation. Score ranges from 1 (strongly agree) to 5 (strongly disagree).  





















Table 2. Moderational effects between quality-of-life scales and psychological distress on 
decision regret; multiple linear regression analyses summary 
 
  Unstandardized 
coefficients 
Standardized 
coefficient   
 Model B Std. Error β t p 
1 (Constant) 2.187 12.987  0.168 0.866 
  Functional status -0.166 0.055 -0.205 -3.019 0.003 
  PD 0.332 0.148 0.153 2.243 0.025 
2 (Constant) -79.959 31.343  -2.551 0.011 
  Functional status 0.852 0.358 1.056 2.379 0.018 
  PD 1.485 0.427 0.682 3.477 0.001 
  Functional*PD -0.015 0.005 -0.964 -2.874 0.004 
 Note. PD: Psychological distress 
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